Company* |
Company* |
Product | Terms/Details (Date) |
Althea |
Altus Pharmaceuticals Inc. (ALTU) |
Althea will manufacture materials for Phase III trials of Altus' ALTU-238 |
The product is a crystallized formulation of human growth hormone; terms of the contract were not disclosed (8/22) |
Carna |
Bio-Connect BV* (the Netherlands) and KinaseDetect ApS* (Denmark) |
The companies entered agreements for distribution of protein kinases from Carna |
Bio-Connect got rights in much of Western Europe, while KinaseDetect got rights in Scandinavia (8/4) |
Isis |
Bruker Daltonics Inc. (unit of Bruker Biosciences Corp; BRKR) |
Deal covering the manufacturing and distribution of Isis' Ibis T5000 biosensor system |
Bruker will be the worldwide manufacturer of the system, which is used to identify infectious organisms in a sample, and will sell it in much of the world (7/31) |
Omnia |
Potentia Pharmaceuticals Inc.* |
Deal under which Omnia will provide Potentia cGMP manufacturing services |
Terms of the master services agreement were not disclosed (8/8) |
Phyton Biotech |
Insmed Inc. (INSM) |
Phyton will use its plant cell fermentation technology to develop a manufacturing process for Insmed's iPlex product |
The process could be used to meet future demand of the product, which is approved to treat growth failure in children with severe primary IGF-1 deficiency (7/31) |
Valentis Inc. |
Cobra Biologics Ltd (UK; AIM:CBF) |
Cobra acquired certain biomanufacturing rights and intellectual property |
Valentis, which was downsizing following a Phase IIb trial failure, gets an undisclosed payment in the deal (8/7) |
XOMA Ltd. |
AVEO Pharmaceuticals Inc.* |
XOMA will manufacture the anti-HGF antibody AV-299 in support of early clinical trials |
The deal is worth $6M to XOMA, which earlier humanized the antibody (9/28) |
Notes: | |||
* Private companies are indicated with an asterisk. | |||
# Item occurred before the time frame of this chart but was not included in the previous chart. | |||
Unless otherwise noted, stock symbols listed are on the Nasdaq market. | |||
AIM = Alternative Investment Market. | |||
To read more on related topics, click on one of the words below.